A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

This study will evaluate the effectiveness and safety of HRS-4642 in combination with nab-paclitaxel and gemcitabine (AG regimen) as conversion therapy for patients with locally advanced pancreatic cancer. Participants will undergo regular assessments, including imaging scans and CA19-9 biomarker tests. If disease recurrence is suspected, unscheduled evaluations may be performed. For participants who discontinue treatment due to reasons other than disease progression (e.g., toxicity), tumor assessments will continue as scheduled until progression, loss to follow-up, death, consent withdrawal,

Trial Details

NCT ID
NCT07438106
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HRS-4642 Injection
Locations (sample)
  • Nanjing, China|32.06167,118.77778

Key Eligibility Criteria

  • Participants must meet all of the following criteria to be eligible for this study:
  • Age ≥18 years and ≤75 years, regardless of gender.
  • Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  • Radiologically confirmed locally advanced disease, defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →